Abstract：Objective: To investigate the incidence and risk factors of iodixanol-induced delayed hypersensitive reactions in patients undergoing digital subtraction angiography (DSA). Methods: This study was carried out in the Second Affiliated Hospital of Xi’an Jiaotong University. Totally 235 patients who used iodixanol as iodinated contrast media (ICM) for DSA were included from January to October 2016. Various information was recorded, including patient age, gender, risk factor (hypertension, diabetes mellitus, renal disease, cardiopulmonary disease, previous food and drug allergy, repeated administration of ICM, treatment with ACE inhibitors, β-blockers, or IL-2), iodixanol information (strengths, total dosage and administration), information of delayed hypersensitive reactions (occurrence time, clinical feature, outcome, et al). The incidence and risk factors of iodixanol-induced delayed hypersensitive reactions were analyzed using logistic regression analysis. Results: The incidence of iodixanol-induced delayed hypersensitive reactions was 6.38% in our hospital, and age (OR =0.937, P =0.007) was an independent risk factor for the reactions. Conclusion: The incidence of iodixanol-induced delayed hypersensitive reactions is high in our hospital, and age is an independent risk factor for the reactions.
[1] Ingelmo R, Diaz D, Moreno C, et al. Clinical Practice Guidelines for Diagnosis and Management of Hypersensitivity Reactions to Contrast Media[J]. J Investig Allergol Clin Immunol, 2016, 26(3): 144-155.
[2] 陈韵岱, 陈纪言, 傅国胜, 等. 碘对比剂血管造影应用相关不良反应中国专家共识[J]. 中国介入心脏病学杂志, 2014, 22(6):341- 348.
[3] 明强, 苏杨, 刘伟静, 等. 临床应用碘对比剂碘克沙醇致触发性药物不良反应及危险因素分析[J]. 中国循环杂志, 2014, 29(11):903- 906.
[4] 魏庆宇, 李全生. 药物过敏国际共识（2014 版）解读[J]. 医学与哲学, 2015, 36(529):31-35.
[5] Yoshikawa H. Late adverse reactions to nonionic contrast media[J]. Radiology, 1992, 183(3):727-740.
[6] Xiao Y, Zeng G, Liu X, et al. Safety enhancement in adult body computed tomography scanning: comparison of iodixanol versus iohexol[J]. Springer Plus, 2016, 24(5):148-154.
[7] Karoline M, Michael L, Norbert H, et al. Intra-arterial and intravenous applications of iosimenol 340 injection,a new non-ionic, dimeric, iso-osmolar radiographic contrast medium: phase 2 experience[J]. Acta Radiologica, 2015, 56(6):702-708.
[8] Munechika H, Hiramatsu Y, Kudo S, et al. A prospective survey of delayed adverse reactions to iohexol in urography and computed tomography[J].European Radiology, 2003, 13(1):185-194.
[9] Brockow K, Christiansen C, Kanny G, et al. Management of hypersensitivity reactions to iodinated contrast media[J].Allergy, 2005, 60(2): 150-158.
[10] Scherer K, Harr T, Bach S, et al. The role of iodine in hypersensitivity reactions to radio contrast media[J].Clinical Experimental Allergy, 2009, 40(3):468-475.
[11] Kanny G, Pichler W, Morisset M, et al. T cell-mediated reactions to iodinated contrast media: Evaluation by skin and lymphocyte activation tests[J]. J Allergy and Clin Immunology, 2005, 115(1):179- 185.
[12] Ozlem G, Omur A, Cetin A, et al. Hypersensitivity Reactions to Contrast Media: Prevalence, Risk Factors and the Role of Skin Tests in Diagnosis-A Cross-Sectional Survey[J].Int Arch Allergy Immunol, 2011, 155(3):297-305.
[13] Kopp A F, Mortele K J, Cho Y D, et al. Prevalence of acute reactions to iopromide: postmarket- ing surveillance study of 74, 717 patients[J]. Acta Radiol, 2008, 49(8):902-911.
[14] H?ussler. Safety and patient comfort with iodixanol: a postmarketing surveillance study in 9515 patients undergoing diagnostic CT examinations[J]. Acta Radiol, 2010, 51(8):924-933.
2017, Vol. 15 
